{{chembox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 407386127
| ImageFile=Guanadrel.png
| ImageSize=
| IUPACName=2-(1,4-Dioxaspiro[4.5]decan-2-ylmethyl)guanidine
| OtherNames=
|Section1={{Chembox Identifiers
| IUPHAR_ligand = 7193
| CASNo_Ref = {{cascite|correct|CAS}}
| CASNo = 40580-59-4
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII =  765C9332T4 
| PubChem=38521
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 5555
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D08029
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1037
| SMILES=C1CCC2(CC1)OCC(O2)CN=C(N)N
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 35305
| InChI = 1/C10H19N3O2/c11-9(12)13-6-8-7-14-10(15-8)4-2-1-3-5-10/h8H,1-7H2,(H4,11,12,13)
| InChIKey = HPBNRIOWIXYZFK-UHFFFAOYAB
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C10H19N3O2/c11-9(12)13-6-8-7-14-10(15-8)4-2-1-3-5-10/h8H,1-7H2,(H4,11,12,13)
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = HPBNRIOWIXYZFK-UHFFFAOYSA-N
| RTECS = 
| MeSHName = C004945

  }}
|Section2={{Chembox Properties
| C=10 | H=19 | N=3 | O=2 
| Appearance=
| Density=
| MeltingPt=
| BoilingPt=
| Solubility=
  }}
|Section3={{Chembox Hazards
| MainHazards=
| FlashPt=
| AutoignitionPt =
  }}
}}
'''Guanadrel''' is an [[antihypertensive agent]].<ref name="pmid4031111">{{cite journal  |vauthors=Oren A, Rotmensch HH, Vlasses PH, etal |title=A dose-titration trial of guanadrel as step-two therapy in essential hypertension |journal=J Clin Pharmacol |volume=25 |issue=5 |pages=343–6 |year=1985 |pmid=4031111 |doi= 10.1002/j.1552-4604.1985.tb02852.x|url=http://jcp.sagepub.com/cgi/pmidlookup?view=long&pmid=4031111}}</ref> It is used in the form of its [[sulfate]].

==Mechanism of action==
Guanadrel is a postganglionic adrenergic blocking agent. Uptake of guanadrel and storage in sympathetic neurons occurs via the [[norepinephrine]] pump; guanadrel slowly displaces norepinephrine from its storage in nerve endings and thereby blocks the release of norepinephrine normally produced by nerve stimulation. The reduction in neurotransmitter release in response to [[sympathetic nerve]] stimulation, as a result of [[catecholamine]] depletion, leads to reduced arteriolar [[vasoconstriction]], especially the reflex increase in sympathetic tone that occurs with a change in position.  Guanadrel is rapidly and well absorbed from gastrointestinal tract.<ref>[http://www.pharmgkb.org/do/serve?objId=PA449821&objCls=Drug#tabview=tab1 Guanadrel], from Pharmacogenetics Knowledge Base</ref>

In 1981 the [[JAMA (journal)|JAMA]] reported guanadrel as an effective step II or step III treatment of hypertension.<ref name="245/16/1639">{{cite journal |author=M. I. Dunn and J. L. Dunlap |title=Guanadrel. A new antihypertensive drug |journal=JAMA |volume=245 |issue=16 |year=1981 |url=http://jama.ama-assn.org/cgi/content/abstract/245/16/1639 |pmid=7206175 |doi=10.1001/jama.1981.03310410017019 |pages=1639–42}}</ref>

==Chemistry==
Guanadrel can be synthesized when [[cyclohexanone]] undergoes ketalization by 3-chloro-1,2-propanediol, forming 2-chloromethyl-1,4-dioxyspiro[4,5]decane, which is further reacted with sodium phthalimide.<ref>W.R. Hardie, J.E. Aaron, {{Cite patent|FR|1522153}} (1968)</ref><ref>W.R. Hardie, J.E. Aaron, S. Afr. Pat. 67 06.328 (1968)</ref><ref>J.E. Aaron, W.R. Hardie, {{US Patent|3547951}} (1970)</ref> After alkaline hydrazinolysis, the resulting phthalimide derivative is transformed into 2-aminomethyl-1,4-dioxyspiro[4,5]decane, which is reacted with S-methylthiourea, giving the desired guanadrel.

:[[File:Guanadrel synthesis.png|800px|left|thumb|Guanadrel synthesis]]{{clear left}}

==References==
{{Reflist}}

==External links==
* [http://www.mayoclinic.com/health/drug-information/DR600737 webpage on guanadrel], from [[Mayo Clinic]]

{{Antihypertensives}}
{{Monoamine reuptake inhibitors}}

[[Category:Ketals]]
[[Category:Guanidines]]
[[Category:Antihypertensive agents]]